Epidemiological characteristics and risk factors associated with post covid-19 thromboembolic events in a tertiary level hospital in Colombia
Características epidemiológicas y factores de riesgo asociados a eventos tromboembólicos post covid-19 en un hospital de tercer nivel en Colombia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
NOVA by http://www.unicolmayor.edu.co/publicaciones/index.php/nova is distributed under a license creative commons non comertial-atribution-withoutderive 4.0 international.
Furthermore, the authors keep their property intellectual rights over the articles.
Show authors biography
Introduction. Thromboembolic events trigger significant morbidity and mortality, high rates of hospital readmissions, poor patient quality of life, and a considerable economic impact. Objective: To characterize epidemiologically the risk factors associated with thromboembolic events post COVID-19 in a tertiary level hospital in Colombia. Methodology. A descriptive cross-sectional study was carried out with the review of 501 medical records of patients over 18 years of age who had suffered a thromboembolic event during January 2021-December 2022. Categorical variables were analyzed using Fisher or chi-square tests. Univariate and multivariate logistic regression was used to assess the effects of thromboembolic complications. Patient survival was analyzed according to the Kaplan-Meier method. Values of p<0.05 were considered significant. Results. CVA (OR=3.099; 95%CI:1.509-6.364, p=0.002) and DVT (OR=3.921, 95%CI:1.577-9.708, p=0.003) were significant in patients with a clinical history of COVID-19 disease. CVA was positively associated with death in the patients studied (OR=1.945; 95%CI:1.093-4.065, p=0.016). Patients older than 71 years, hypertensive or with COPD had a higher risk of death due to a thromboembolic event. Conclusion. In this study, stroke and ischemic heart disease were the most common thromboembolic events. Survival was influenced by hypertension, CKD or COPD as associated risk factors for death due to a thromboembolic event. In patients with a history of COVID-19 infection, CVA and DVT were the most significant.
Conclusions: CVA and myocardial Ischemia were the most frequently encountered thromboembolic events. Survival was influenced by hypertension or COPD. In patients with a history of COVID-19 infection, CVA and DVT were the most significant.
Article visits 52 | PDF visits 23
Downloads
1. Marcos P J, Vilariño-Pombo C, Pavón-Freire J, Marcos-Velázquez P. Enfermedad tromboembólica venosa y tromboembolismo pulmonar. Med-Programa Form Médica Contin Acreditado. 2010;10(66):4513–9. https://doi.org/10.1016/S0304-5412(10)70206-7.
2. Organización Mundial de la Salud (OMS). Enfermedades cardiovasculares. [Internet] 2022. [Consultado Noviembre 6 de 2023] Disponible en: https://www.who.int/es/health-topics/cardiovascular-diseases#tab=tab_1.
3. Konstantinides S V, Meyer G, Becattini C, Bueno H, Geersing G J, Harjola V P, et al. Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):1901647. https://doi.org/10.1183/13993003.01647-2019
4. Nápoles-Méndez D, Couto-Núñez D. Utilización de los factores de riesgo y modelos clínicos predictivos para el diagnóstico de la enfermedad tromboembólica venosa. MediSan. 2015;19(1):88–101.
5. Lalor N, Raffaeli A, Torres, Silveyra D, Aphalo V, Scapellato J L.. Complicaciones tromboembólicas de los pacientes internados por COVID-19. Medicina (B. Aires). 2022; 82(1): 21-27.
6. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020;295(3):715-721. https://doi.org/10.1148/radiol.2020200370..
7. Ma A, Kase C S, Shoamanesh A, Abdalkader M, Pikula A, Sathya A, et al. Stroke and Thromboprophylaxis in the Era of COVID-19. J Stroke Cerebrovasc Dis. 2021; 30(1):105392. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105392
8. Deshpande C. Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism? Ann Intern Med. 2020;173(5):394-395. https://doi.org/10.7326/M20-3255.
9. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation. 2020;142(2):184-186. https://doi.org/10.1161/CIRCULATIONAHA.120.047430.
10. Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. https://doi.org/10.1016/0021-9681(87)90171-8.
11. Lippi G, Favaloro E J. Venous and Arterial Thromboses: Two Sides of the Same Coin? Semin Thromb Hemost. 2018;44(3):239-248. https://doi.org/10.1055/s-0037-1607202
12. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424. https://doi.org/10.1111/jth.14830..
13. Guzman S, Rodriguez D, Bastidas B, Londoño H. Comportamiento de la enfermedad tromboembólica venosa en un centro hospitalario de la ciudad de Popayán, Colombia. Revista Salud Bosque. 2021; 11(1): 1–18. https://doi.org/10.18270/rsb.v11i1.3351.
14. Klok F A, Kruip M J H A, van der Meer N J M, Arbous M S, Gommers D A M P J, Kant K M, et al. Incidence of thrombotic complicationsin critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-147. https://doi.org/10.1016/j.thromres.2020.04.013
15. Lima da Silva L, Barros E, Silva P. Estratificação de risco para tromboembolismo venoso em pacientes de um hospital público do distrito federal. Cogitare enferm. 2019;24:56741. https://doi.org/10.5380/ce.v24i0.56741
16. Organización Mundial de la Salud (OMS). Principales causas de muerte y discapacidad en el mundo: 2000-2019. [Internet] 2019. [Consultado 20 de nov 2023] Disponible en: https://www.who.int/es/news/item/09-12-2020-whoreveals-leading-causes-of-death-and-disability-worldwide-2000-2019
17. Machado J, Machado M. Prevalencia de factores de riesgo cardiovascular en pacientes con dislipidemia afiliados al sistema de salud en Colombia. Rev Peru Med Exp Salud Publica. 2013; 30(2):205-11.
18. Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014;44(1):93–102. https://doi.org/10.1111/eci.12181
19. Man S F, Van Eeden S, Sin D D. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiol. 2012;28(6):653–661. https://doi.org/10.1016/j.cjca.2012.06.013
20. Morgan A D, Herrett E, De Stavola B L, Smeeth L, Quint J K. COPD disease severity and the risk of venous thromboembolic events: a matched case-control study. Int J Chron Obstruct Pulmon Dis. 2016; 28;11:899-908. doi: 10.2147/COPD.S100533.
21. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020;92(10):1915-1921. https://doi.org/10.1002/jmv.25889
22. Montufar F, Díaz G, Matiz C, Ali A, Pacheco M. Exacerbación aguda de EPOC en la época de COVID-19. Rev Colomb Neumol. 2020; 32 (1):47-57. https://doi.org/10.30789/rcneumologia.v32.n1.2020.510
23. Guan W J, Liang W H, Zhao Y, Liang H R, Chen Z S, Li Y M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May 14;55(5):2000547. https://doi.org/10.1183/13993003.00547-2020
24. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. https://doi.org/10.1001/jama.2020.5394.
25. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk
factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021; 20: 795–820. https://doi.org/10.1016/S1474-4422(21)00252-0
26. Gaviria S, Ramírez A, Alzate M, Contreras H, Jaramillo N, Muñoz MC. Epidemiología del síndrome coronario agudo. Med UPB. 2020;39(1):49-56. https://doi.org/10.18566/medupb.v39n1.a08
27. Cantú-Brito C, Chiquete E, Ruiz-Sandoval J L, Gaxiola E, Albuquerque D C, Corbalán R, et al. Atherothrombotic disease, traditional risk factors, and 4-year mortality in a Latin American population: the REACH Registry. Clin Cardiol. 2012;35(8):451-7. https://doi.org/ 10.1002/clc.22005.
28. Martínez-Espitia E, Méndez-Muñoz P C, Paba-Rojas C E, Rodríguez-Perdomo J, Silva-Hernández LM. Mortalidad por enfermedad isquémica cardiaca según variables sociodemográficas en Bogotá, Colombia. Rev. salud. bosque. 2020;10(1):1-14. https://doi.org/10.18270/rsb.v10i1.2828
29. Bikdeli B, Madhavan M V, Jimenez D, Chuich T, Dreyfus I, Driggin E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020; S0735–1097. https://doi.org/10.1016/j.jacc.2020.04.03. 3500
30. Li P, Zhao W, Kaatz S, Latack K, Schultz L, Poisson L. Factors Associated With Risk of Postdischarge Thrombosis in Patients With COVID-19. JAMA Netw Open. 2021; 4(11):e2135397 .https://doi.org/10.1001/jamanetworkopen.2021.35397.
31. Wendelboe A M, Raskob G E. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016;118(9):1340-7. https://doi.org/10.1161/CIRCRESAHA.115.306841.
32. Ramírez-Arias E, Rosas-Peralta M, Borrayo-Sánchez G, Moreno-Ruiz LA, Arenas-Fonseca JG, Arzola-Covarrubias VM, et al. Tromboembolismo pulmonar: experiencia reciente de 4 años en un hospital de cardiología. Rev Med Inst Mex Seguro Soc. 2017; 55(1):52–62.
33. Castejón B, Morillo R, Barrios D, Nieto R, Jaureguizar A, Portillo AK, et al. Significado pronóstico de la trombosis venosa profunda asintomática en pacientes con tromboembolia de pulmón aguda sintomática. Angiología 2016; 68(4):298–303.
34. Brækkan S K, Hansen J B. VTE epidemiology and challenges for VTE prevention at the population level, Thromb update. 2023; 10:100132. https://doi.org/10.1016/j.tru.2023.100132.
Information
Keywords
